Capstone Wealth Management Group (Oregon)’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-7,755
Closed -$470K 128
2026
Q1
$470K Sell
7,755
-73
-0.9% -$4.26K 0.29% 74
2025
Q4
$422K Buy
7,828
+1,800
+30% +$86.6K 0.26% 72
2025
Q3
$272K Hold
6,028
0.17% 96
2025
Q2
$279K Hold
6,028
0.2% 80
2025
Q1
$368K Hold
6,028
0.29% 63
2024
Q4
$341K Buy
+6,028
New +$337K 0.26% 72

Other funds holding BMY

Capstone Wealth Management Group (Oregon)'s BMY Position: Q2 2026 in Review

Capstone Wealth Management Group (Oregon) sold out of Bristol-Myers Squibb (BMY) in Q2 2026, closing a stake of 7,755 shares — an estimated $470K sold.

Capstone Wealth Management Group (Oregon) first reported a position in BMY in Q4 2024 and held it in 6 quarters. The position peaked at $470K in Q1 2026. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Capstone Wealth Management Group (Oregon) reported no remaining Bristol-Myers Squibb position as of Q2 2026 after selling out during the quarter.
  • Capstone Wealth Management Group (Oregon) sold 7,755 Bristol-Myers Squibb shares in Q2 2026, an estimated $470K.
  • Capstone Wealth Management Group (Oregon) first reported a position in Bristol-Myers Squibb in Q4 2024 and held it in 6 quarters.
  • Capstone Wealth Management Group (Oregon)'s Bristol-Myers Squibb position peaked at $470K in Q1 2026.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Capstone Wealth Management Group (Oregon)'s 13F filing for Q2 2026, filed 27 Jul 2026.